Obsidian Therapeutics, Inc. (OBX)
A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Obsidian Therapeutics Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 61.77M shares outstanding
No company description available.
Leadership
Madan Jagasia
President, CEO & Director
Parameswaran Hari
Chief Medical Officer
Dana Alexander
Chief Technical Officer
Maria Fardis
Executive Chairman of the Board
Employees
--
Country
--
Sector
Healthcare
Website
--
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 ROSS ROBERT W. | Director | Grant/Award | 37.7K | -- | Aug 3, 2026 |
 Norkunas Matthew | Director | Grant/Award | 37.7K | -- | Aug 3, 2026 |
 Jagasia Madan | Chief Executive Officer | Grant/Award | 37.7K | -- | Aug 3, 2026 |
 Barrett Peter | Director | Grant/Award | 37.7K | -- | Aug 3, 2026 |
 Hagen Heidi | Director | Grant/Award | 37.7K | -- | Aug 3, 2026 |
 Fardis Maria | Director | Grant/Award | 37.7K | -- | Aug 3, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Paradigm BioCapital Advisors LP · joint filing· may incl. warrants· filed Oct 2026 | 4.1M | 6.6% | 13G |
 Norkunas Matthew Director | 30.9K | 0.1% | FORM 4 |
SBI Securities Co., Ltd. | 1 | 0.0% | 13F |
Insiders
- ROSS ROBERT W.Director
- Norkunas MatthewDirector
- Jagasia MadanChief Executive Officer
- Barrett PeterDirector
- Hagen HeidiDirector
- Fardis MariaDirector
Top institutional holders
based on 61.77M shares outstanding
30d Avg
343.39K
60d Avg
499.85K
90d Avg
392.25K